These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32730095)

  • 1. COVID-19: a wreak havoc across the globe.
    Rehman H; Ahmad MI
    Arch Physiol Biochem; 2023 Feb; 129(1):82-94. PubMed ID: 32730095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
    Martinez MA
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 in Children: Clinical Approach and Management.
    Sankar J; Dhochak N; Kabra SK; Lodha R
    Indian J Pediatr; 2020 Jun; 87(6):433-442. PubMed ID: 32338347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19: breaking down a global health crisis.
    Mallah SI; Ghorab OK; Al-Salmi S; Abdellatif OS; Tharmaratnam T; Iskandar MA; Sefen JAN; Sidhu P; Atallah B; El-Lababidi R; Al-Qahtani M
    Ann Clin Microbiol Antimicrob; 2021 May; 20(1):35. PubMed ID: 34006330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding the binding mechanism for potential inhibition of SARS-CoV-2 Mpro and exploring the modes of ACE2 inhibition by hydroxychloroquine.
    Choudhury M; Dhanabalan AK; Goswami N
    J Cell Biochem; 2022 Feb; 123(2):347-358. PubMed ID: 34741481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use.
    Bhatnagar T; Murhekar MV; Soneja M; Gupta N; Giri S; Wig N; Gangakhedkar R
    Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):184-189. PubMed ID: 32362644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
    Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
    Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment options for COVID-19: The reality and challenges.
    Jean SS; Lee PI; Hsueh PR
    J Microbiol Immunol Infect; 2020 Jun; 53(3):436-443. PubMed ID: 32307245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
    Giovane RA; Rezai S; Cleland E; Henderson CE
    Rev Med Virol; 2020 Sep; 30(5):e2136. PubMed ID: 32644275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis.
    Lecronier M; Beurton A; Burrel S; Haudebourg L; Deleris R; Le Marec J; Virolle S; Nemlaghi S; Bureau C; Mora P; De Sarcus M; Clovet O; Duceau B; Grisot PH; Pari MH; Arzoine J; Clarac U; Boutolleau D; Raux M; Delemazure J; Faure M; Decavele M; Morawiec E; Mayaux J; Demoule A; Dres M
    Crit Care; 2020 Jul; 24(1):418. PubMed ID: 32653015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.
    Kim JW; Kim EJ; Kwon HH; Jung CY; Kim KC; Choe JY; Hong HL
    Korean J Intern Med; 2021 Mar; 36(Suppl 1):S253-S263. PubMed ID: 32536150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.
    Cao B; Wang Y; Wen D; Liu W; Wang J; Fan G; Ruan L; Song B; Cai Y; Wei M; Li X; Xia J; Chen N; Xiang J; Yu T; Bai T; Xie X; Zhang L; Li C; Yuan Y; Chen H; Li H; Huang H; Tu S; Gong F; Liu Y; Wei Y; Dong C; Zhou F; Gu X; Xu J; Liu Z; Zhang Y; Li H; Shang L; Wang K; Li K; Zhou X; Dong X; Qu Z; Lu S; Hu X; Ruan S; Luo S; Wu J; Peng L; Cheng F; Pan L; Zou J; Jia C; Wang J; Liu X; Wang S; Wu X; Ge Q; He J; Zhan H; Qiu F; Guo L; Huang C; Jaki T; Hayden FG; Horby PW; Zhang D; Wang C
    N Engl J Med; 2020 May; 382(19):1787-1799. PubMed ID: 32187464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An update on novel COVID-19 pandemic: a battle between humans and virus.
    Prajapati S; Sharma M; Kumar A; Gupta P; Narasimha Kumar GV
    Eur Rev Med Pharmacol Sci; 2020 May; 24(10):5819-5829. PubMed ID: 32495921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2.
    Atzrodt CL; Maknojia I; McCarthy RDP; Oldfield TM; Po J; Ta KTL; Stepp HE; Clements TP
    FEBS J; 2020 Sep; 287(17):3633-3650. PubMed ID: 32446285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses.
    Kang CK; Seong MW; Choi SJ; Kim TS; Choe PG; Song SH; Kim NJ; Park WB; Oh MD
    Korean J Intern Med; 2020 Jul; 35(4):782-787. PubMed ID: 32460458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addressing the Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hematopoietic Cell Transplantation: Learning Networks as a Means for Sharing Best Practices.
    Ardura M; Hartley D; Dandoy C; Lehmann L; Jaglowski S; Auletta JJ;
    Biol Blood Marrow Transplant; 2020 Jul; 26(7):e147-e160. PubMed ID: 32339662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection.
    Yan D; Liu XY; Zhu YN; Huang L; Dan BT; Zhang GJ; Gao YH
    Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32430428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021).
    Panovska-Stavridis I; Ridova N; Stojanoska T; Demiri I; Stevanovic M; Stojanovska S; Ristevska T; Dimkovski A; Filipce V; Dimovski A; Grozdanova A
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2021 Apr; 42(1):5-18. PubMed ID: 33894123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.